Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans

J Physiol. 2003 Oct 1;552(Pt 1):223-32. doi: 10.1113/jphysiol.2003.042135. Epub 2003 Jul 7.

Abstract

Active vasodilatation (AVD) in human, non-glabrous skin depends on functional cholinergic fibres but not on acetylcholine (ACh). We tested whether AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released from cholinergic nerves. (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis. Skin blood flow (SkBF) was continuously monitored by laser Doppler flowmetry (LDF). Mean arterial pressure (MAP) was measured non-invasively and cutaneous vascular conductance (CVC) calculated as LDF/MAP. Subjects were supine and wore water-perfused suits to control whole-body skin temperature (Tsk) at 34 degrees C. Concentrations of 54 microM, 107 microM, or 214 microM VIP(10-28) were perfused via intradermal microdialysis at 2 microl min-1 for approximately 1 h. Then 7.5 microM VIP was added to the perfusate containing VIP(10-28) at the three concentrations or Ringer solution and perfusion was continued for 45-60 min. At the control site, this level of VIP caused approximately the vasodilatation typical of heat stress. All VIP(10-28)-treated sites displayed an attenuated dilatation in response to the VIP. The greatest attenuation was observed at the site that received 214 microM VIP(10-28) (P < 0.01). (2) We used 214 microM VIP(10-28) alone and with the iontophoretically administered muscarinic receptor antagonist atropine (400 microA cm-2, 45 s, 10 mM) in heated subjects to test the roles of VIP and ACh in AVD. Ringer solution and 214 microM VIP(10-28) were each perfused at two sites, one of which in each case was pretreated with atropine. After 1 h of VIP(10-28) treatment, individuals underwent 45-60 min of whole-body heating (Tsk to 38.5 degrees C). VIP(10-28), alone or in combination with atropine, attenuated the increase in CVC during heat stress, suggesting an important role for VIP in AVD.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Atropine / pharmacology
  • Body Temperature Regulation / physiology*
  • Cholinergic Fibers / drug effects
  • Cholinergic Fibers / physiology
  • Female
  • Heat Stress Disorders / physiopathology*
  • Humans
  • Laser-Doppler Flowmetry
  • Male
  • Microdialysis
  • Parasympatholytics / pharmacology
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / physiology
  • Skin / blood supply*
  • Skin / innervation
  • Skin Temperature / drug effects
  • Skin Temperature / physiology
  • Vasoactive Intestinal Peptide / administration & dosage*
  • Vasodilation / drug effects*

Substances

  • Parasympatholytics
  • Peptide Fragments
  • Vasoactive Intestinal Peptide
  • vasoactive intestinal peptide (10-28)
  • Atropine